How South Shore schools will handle masks after state mandate ends patriotledger.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from patriotledger.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BALTIMORE, May 26, 2021 /PRNewswire/ Prosit Sole Biotechnology, a clinical-stage biotech company developing novel protein therapeutics, today announces that it has initiated the first-in-human ( FIH ) Phase I clinical trial of PSP001 in US. PSP001 is a novel, long acting and potent interferon lambda chimera injection. The first dose was administered on May 25, 2021.
Type III interferons (IFN s), also termed interferon lambda s (IFNλ s) constitute a new addition to the IFN family. Their unique receptor IFNλR1 is particularly abundant at the barrier surfaces, such as the respiratory tracts, the gastrointestinal tracts, and the liver. Non-redundant to type I interferons (IFNα and IFNβ), IFNλ s exhibit unique antiviral and immune modulatory activities. Prosit Sole Biotechnology is developing PSP001 for the treatment of chronic norovirus enteritis in hematopoietic and solid organ transplant recipients.